A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma is a phase 3 interventional study registered as NCT05732805, led by Biocad, and active but no longer recruiting on the registry. Official title: A Double-Blind Placebo-Controlled Comparative Randomised Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma. Planned enrolment is 270 participants (estimated). The study started in 2022-08-02 and primary completion is expected in 2024-06-20. No results have been posted on ClinicalTrials.gov.